Chemotherapy and targeted therapy combinations in advanced melanoma.

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18

Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96

MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93

Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest (2008) 1.89

Retracted Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species. Ann Biomed Eng (2010) 1.54

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36

Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch (2007) 1.26

Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol (2008) 1.21

The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14

Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08

Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin (2007) 1.01

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res (2011) 1.01

Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89

Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One (2009) 0.89

Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88

Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther (2014) 0.88

Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) (2007) 0.85

Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther (2009) 0.85

Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther (2008) 0.82

Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Mol Pharm (2015) 0.82

Current research and development of chemotherapeutic agents for melanoma. Cancers (Basel) (2010) 0.81

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One (2014) 0.81

DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria. Sci Rep (2015) 0.81

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer (2011) 0.80

Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol (2010) 0.79

Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract (2011) 0.79

Systemic therapy of non-resectable metastatic melanoma. Cancers (Basel) (2010) 0.78

The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics (2007) 0.77

Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents. Bioorg Med Chem (2010) 0.76

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma-Derived Oxidants. Oxid Med Cell Longev (2017) 0.76